Clinical Study

Prognostic Value of Classifying Parapharyngeal Extension in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging

Guo-Yi Zhang,1 Ying Huang,2 Xue-Feng Hu,1 Xiang-Ping Chen,1 Tao Xu,1 Li-Zhi Liu,3 Wei-Hong Wei,1 Guo-Sen Huang,1 Miao-Miao Zhou,1 Ze-Li Huang,1 and Yue-Jian Wang1

1Cancer Center, Cancer Research Institute, Foshan Hospital, Sun Yat-sen University, Foshan, Guangdong 528000, China
2Department of Radiation Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China
3Imaging Diagnosis and Interventional Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China

Correspondence should be addressed to Yue-Jian Wang; wyjian01@163.com

Received 4 June 2014; Accepted 29 July 2014

Academic Editor: An Liu

Copyright © 2015 Guo-Yi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To subclassify parapharyngeal extension in nasopharyngeal carcinoma (NPC) and investigate its prognostic value and staging categories based on magnetic resonance imaging (MRI).

Methods and Materials. Data from 1504 consecutive NPC patients treated with definitive-intent radiotherapy were analyzed retrospectively. Sites of parapharyngeal extension were defined by MRI. Overall survival (OS), local relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) were calculated by the Kaplan-Meier method and compared with the log-rank test. Hazard consistency and hazard discrimination were determined by multivariate analysis with Cox proportional hazards models.

Results. 1104 patients (73.4%) had parapharyngeal extension; 1.7–63.8% had involvement of various anatomic sites. The hazard ratio for death was significantly higher with extensive parapharyngeal extension (lateral pterygoid muscle of masticator space and beyond or parotid space) than with mild extension (medial pterygoid muscle of masticator space, or carotid, prevertebral, or retropharyngeal space). OS, LRFS, and DMFS with extensive parapharyngeal extension were similar to those in T4 disease; OS, LRFS, and DMFS with mild parapharyngeal extension were significantly higher than in those T3 disease (all P ≤ 0.015).

Conclusions. Parapharyngeal extension in NPC should be subclassified as mild or extensive, which should be regarded as stages T2 and T4 diseases, respectively.

1. Introduction

Nasopharyngeal carcinoma (NPC) has a strong invasive tendency and often develops parapharyngeal extension, with a prevalence of 72–83% at diagnosis [1–10]. Parapharyngeal extension in NPC indicates tumor invasion beyond the pharyngobasilar fascia and into the parapharyngeal, masticator, prevertebral, or parotid space, which are separated by the cervical fascias; the parapharyngeal space can be subdivided into the prestyloid, carotid, and retropharyngeal spaces (Figure 1).

The prognostic significance of parapharyngeal extension in NPC has not been resolved [1–12] and the recommendations in published staging systems pertaining to parapharyngeal extension are ambiguous [13–16]. Chua et al. [1] reported that lateral tumor invasion beyond the line joining the free edge of the medial pterygoid plate to the styloid process was an independent prognostic factor. Other studies have shown that parapharyngeal extension or posterolateral tumor invasion beyond a line drawn from the styloid process to the midpoint of the posterior edge of the great occipital foramen also has some value as an indicator of poorer prognosis [3–5]. However, using the American Joint Committee on Cancer (AJCC) definition of parapharyngeal extension beyond the pharyngobasilar fascia or subclassifying the degree of parapharyngeal extension according to the presence or absence of carotid space...
Figure 1: Axial section through the nasopharynx showing the relationship between various anatomic sites of parapharyngeal extension surrounding the nasopharynx, which are divided by the three layers of the cervical fascia: deep (dark blue line), middle (bright green line), and superficial (orange line). Parapharyngeal extension includes involvement of the masticator space (MS, blue), prestyloid space (PSS, purple), carotid space (CS, green), retropharyngeal space (RPS, pink), prevertebral space (PVS, yellow), and parotid space (PS, brown). Compared with the anatomic masticator space, the staging masticator space (the region within the red line) excludes the medial and lateral pterygoid muscles but includes the retromaxillary fat pad. MP: medial pterygoid muscle; LP: lateral pterygoid muscle; M: masseter muscle; T: temporalis muscle; RT: retromaxillary fat pad.

Involvement, parapharyngeal extension had no prognostic significance in NPC [7–10]. The definitions of parapharyngeal extension used in these studies vary widely, and most patients were staged on the basis of computed tomography (CT) scans. Conversely, two studies based on magnetic resonance imaging (MRI) suggested that involvement of any part of the anatomic masticator space should be regarded as T4 disease [11,12].

In light of these discrepancies, this study aimed to identify appropriate subclassifications (lateral, posterior, posterolateral, and inferior spread) for parapharyngeal extension in NPC and to reassess the prognostic value and staging categories for parapharyngeal extension based on MRI in patients with NPC treated with definitive-intent radiotherapy.

2. Materials and Methods

2.1. Patients. This retrospective study was approved by the institutional review board and all examinations were performed after written informed consent had been obtained from the patients or their next of kin. From December 2002 to October 2006, 1504 ethnic Chinese patients (1145 males, mean age 46 years, range 13–76 years; 358 females, mean age 43 years, range 18–75 years) with newly diagnosed, untreated, and nondisseminated NPC who were subsequently treated with definitive-intent radiotherapy were enrolled in the study. Patients whose treatment deviated from institutional guidelines due to advanced age or organ dysfunction were excluded. All patients underwent pretreatment evaluation including MRI of the neck and nasopharynx, chest radiography, abdominal sonography, and a whole-body bone scan. Medical records and imaging studies were reviewed and all patients were restaged according to the 2010 AJCC TNM staging system for NPC [15]. Table 1 shows the patients’ pathologic classification, T classification, N classification, and overall stage.

Table 1: Characteristics of 1504 patients with nasopharyngeal carcinoma.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number of patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO pathologic classification</td>
<td></td>
</tr>
<tr>
<td>Type 1</td>
<td>17 (1.1)</td>
</tr>
<tr>
<td>Type 2</td>
<td>168 (11.2)</td>
</tr>
<tr>
<td>Type 3</td>
<td>1319 (87.7)</td>
</tr>
<tr>
<td>T classification</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>278 (18.5)</td>
</tr>
<tr>
<td>T2</td>
<td>220 (14.6)</td>
</tr>
<tr>
<td>T3</td>
<td>587 (39.0)</td>
</tr>
<tr>
<td>T4</td>
<td>419 (27.9)</td>
</tr>
<tr>
<td>N classification</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>344 (22.9)</td>
</tr>
<tr>
<td>N1</td>
<td>901 (59.9)</td>
</tr>
<tr>
<td>N2</td>
<td>207 (13.8)</td>
</tr>
<tr>
<td>N3</td>
<td>53 (3.4)</td>
</tr>
<tr>
<td>AJCC 2010 stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>101 (6.7)</td>
</tr>
<tr>
<td>II</td>
<td>311 (20.7)</td>
</tr>
<tr>
<td>III</td>
<td>638 (42.4)</td>
</tr>
<tr>
<td>IV-a-b</td>
<td>454 (30.2)</td>
</tr>
</tbody>
</table>

AJCC: American Joint Committee on Cancer; WHO: World Health Organization.

*Numbers in parentheses are percentages.

2.2. Imaging Protocol. All patients underwent MRI using a 1.5 T system (Signa CV/I; GE Healthcare, Milwaukee, WI) employing a spin echo technique. The region from the suprasellar cistern to the inferior margin of the sternal end of the clavicle was examined with a head and neck combined coil. T1-weighted images in the axial, coronal, and sagittal planes (repetition time 500–600 ms, echo time 10–20 ms) and T2-weighted images in the axial plane (repetition time 4000–6000 ms, echo time 95–110 ms) were obtained before injection of the contrast material. After intravenous injection of Gd-DTPA at a dose of 0.1 mmol/kg body weight, T1-weighted axial and sagittal sequences and T1-weighted fat-suppressed coronal sequences were performed sequentially, with parameters similar to those used before Gd-DTPA injection. The section thicknesses and interslice gaps were 5 mm and 1 mm for the axial plane and 6 mm and 1 mm for the coronal and sagittal planes.

2.3. Image Assessment. Two experienced radiologists (Y.Z.L. and L.Z.L., with 10 and 12 years’ experience in MRI of NPC, resp., at the time of the study) separately evaluated
the images. Any disagreements were resolved by consensus. MRI findings of parapharyngeal extension were assessed at the following sites: medial pterygoid muscle, lateral pterygoid muscle, staging masticator space (tumor involvement beyond the anterior surface of the lateral pterygoid muscle), prestyloid space, retropharyngeal space, anterior carotid space, posterior carotid space (the demarcation of the anterior and posterior carotid space was the posterior edge of the internal jugular vein), prevertebral space, parotid space, and parapharyngeal space (Figure 1). Parapharyngeal extension was defined as parapharyngeal involvement of tumor below the Cl/C2 interspace [3].

2.4. Treatment. All patients were treated with definitive-intent radiotherapy. Most of the patients (805, 53.5%) were treated with conventional techniques based on CT simulation, but 621 (41.3%) patients received intensity-modulated radiation therapy (IMRT) and 78 (5.2%) underwent three-dimensional conformal radiotherapy (3DCRT). Details of the radiotherapy techniques used at our cancer center have been reported previously [17–19].

During the study period, based on the AJCC 2002 staging system, our institutional guidelines recommended radiotherapy alone for stage I disease, concomitant chemoradiotherapy (CCRT) for stage II disease, and induction or adjuvant chemotherapy together with CCRT for stage III to IVB disease. Overall, 101 study patients were treated with radiotherapy only and 317 received CCRT; induction chemotherapy and CCRT were delivered to 423 patients and adjuvant chemotherapy and CCRT were delivered to 663 patients.

2.5. Followup and Statistical Analysis. Complete follow-up data were available for 97.4%, 96.5%, and 73.6% of the 1504 patients at 3 years, 5 years, and 8 years, respectively. The duration of followup was calculated from the first day of treatment to either the day of death or the day of the last examination. Patients were followed up at least once every 3 months during the first 2 years and every 6 months thereafter until death. The median follow-up period was 110 months (range 2–128 months).

SPSS version 16.0 (IBM, Armonk, NY) was used for all statistical analyses and the timing of all events was measured from the start of treatment. The time to the first defining event was assessed for the following end points: overall survival (OS), local relapse-free survival (LRFS), and distant metastasis-free survival (DMFS). Actuarial rates were calculated by the Kaplan-Meier method and compared using the log-rank test [20]. Multivariate analyses using Cox proportional hazards models were employed to test hazard consistency and hazard discrimination by backward elimination of insignificant explanatory variables [21]. Two-tailed $P$ values of $<0.05$ were considered statistically significant.

3. Results

3.1. Pattern of Failure. One hundred and seventy patients (11.3%) developed local recurrence, 220 (14.6%) developed distant metastases, and 446 (29.7%) died. For the entire patient population, 5-year OS, LRFS, and DMFS ± standard deviation were 80.9% ± 1.0%, 89.7% ± 0.8%, and 86.3% ± 0.9%, respectively, and 8-year OS, LRFS, and DMFS were 70.3% ± 1.2%, 87.6% ± 0.9%, and 84.4% ± 1.0%, respectively.

3.2. Prevalence of Parapharyngeal Extension by Anatomic Site. Of the 1504 patients, 1104 (73.4%) were diagnosed with parapharyngeal extension. Among these 1104 patients, the retropharyngeal and prestyloid spaces were the most commonly involved sites, followed by the prevertebral space, anterior carotid space, medial pterygoid muscle, lateral pterygoid muscle, posterior carotid space, parapharyngeal space, parotid space, and staging masticator space, with incidences of 63.8% (960/1504), 62.5% (940/1504), 39.0% (587/1504), 29.4% (442/1504), 20.7% (311/1504), 8.8% (132/1504), 7.4% (111/1504), 3.3% (50/1504), 2.6% (39/1504), and 1.7% (26/1504), respectively. The most common sites of tumor involvement were thus adjacent to the nasopharynx and the least common were more distant to the nasopharynx.

3.3. Subclassification of Masticator, Carotid, and Parapharyngeal Space Extension. The prognostic value of the grade of lateral tumor spread was analyzed to determine an optimal subclassification for masticator space invasion. There was no significant difference in hazard ratio (HR) for OS, LRFS, or DMFS between patients with lateral pterygoid muscle invasion and those with staging masticator space invasion ($P = 0.727$, $P = 0.765$, and $P = 0.842$, resp.), whereas patients with medial pterygoid muscle invasion had significantly lower HRs for death and distant metastasis than those with lateral pterygoid muscle invasion ($P = 0.006$ and $P = 0.011$, resp.) (Table 2). When masticator space invasion was graded as involvement of the medial pterygoid muscle versus involvement of the lateral pterygoid muscle and beyond, significant differences in HRs for death and distant metastasis were observed between the two groups ($P = 0.005$ and $P = 0.006$, resp.; Table 2).

To investigate the prognostic significance of posterolateral or inferior tumor spread, we compared differences in HR between anterior and posterior carotid space involvement and between paranasopharyngeal and parapharyngeal extension. The HRs for OS, LRFS, and DMFS in patients with anterior carotid space invasion were similar to those of patients with posterior carotid space invasion ($P = 0.618$, $P = 0.621$, and $P = 0.085$, resp.), as were these values for patients with parapharyngeal extension compared with patients with paranasopharyngeal extension ($P = 0.482$, $P = 0.072$, and $P = 0.312$, resp.) (Table 2). These results suggest that subclassifications of carotid space or parapharyngeal extension are unnecessary.

3.4. Classification of Parapharyngeal Extension. Based on the above findings, HRs for death according to anatomic site (prestyloid space, carotid space, retropharyngeal space, prevertebral space, medial pterygoid muscle, lateral pterygoid muscle, and beyond, and parotid space) were further analyzed to subclassify parapharyngeal extension. There were significant differences in the HR for death between patients
Table 2: Incidence of tumor parapharyngeal extension by anatomic site.

<table>
<thead>
<tr>
<th>Anatomic site</th>
<th>Death HR* (95% CI)</th>
<th>P</th>
<th>Local failure HR* (95% CI)</th>
<th>P</th>
<th>Distant metastasis HR* (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Masticator space</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>0.551 (0.400–0.760)</td>
<td>&lt;0.001</td>
<td>0.457 (0.267–0.782)</td>
<td>0.004</td>
<td>0.394 (0.256–0.606)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Medial pterygoid muscle</td>
<td>0.623 (0.445–0.873)</td>
<td>0.006</td>
<td>0.940 (0.566–1.561)</td>
<td>0.812</td>
<td>0.584 (0.386–0.884)</td>
<td>0.011</td>
</tr>
<tr>
<td>Lateral pterygoid muscle</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Staging masticator space</td>
<td>0.906 (0.522–1.573)</td>
<td>0.727</td>
<td>1.147 (0.467–2.819)</td>
<td>0.765</td>
<td>1.067 (0.563–2.023)</td>
<td>0.842</td>
</tr>
<tr>
<td><strong>Masticator space</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>0.885 (0.651–1.202)</td>
<td>0.433</td>
<td>0.486 (0.302–0.780)</td>
<td>0.003</td>
<td>0.675 (0.439–1.037)</td>
<td>0.073</td>
</tr>
<tr>
<td>Medial pterygoid muscle</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Lateral pterygoid muscle and beyond</td>
<td>1.572 (1.143–2.163)</td>
<td>0.005</td>
<td>1.091 (0.678–1.754)</td>
<td>0.720</td>
<td>1.734 (1.172–2.567)</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Carotid space</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>0.735 (0.586–0.921)</td>
<td>0.008</td>
<td>0.693 (0.482–0.996)</td>
<td>0.048</td>
<td>0.689 (0.502–0.947)</td>
<td>0.022</td>
</tr>
<tr>
<td>Anterior carotid space</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Posterior carotid space</td>
<td>1.085 (0.787–1.497)</td>
<td>0.618</td>
<td>1.035 (0.802–1.507)</td>
<td>0.621</td>
<td>1.425 (0.952–2.132)</td>
<td>0.085</td>
</tr>
<tr>
<td><strong>Parapharyngeal extension</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>0.678 (0.494–0.931)</td>
<td>0.016</td>
<td>0.659 (0.395–1.099)</td>
<td>0.110</td>
<td>0.832 (0.523–1.325)</td>
<td>0.439</td>
</tr>
<tr>
<td>Paranasopharyngeal</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Paraooropharyngeal</td>
<td>1.169 (0.756–1.809)</td>
<td>0.482</td>
<td>1.734 (0.952–3.158)</td>
<td>0.072</td>
<td>1.257 (0.857–2.213)</td>
<td>0.312</td>
</tr>
</tbody>
</table>

* HR adjusted for age, gender, chemotherapy, T category, and N category according to the seventh edition AJCC system.

Figure 2: HR for death according to anatomic site of parapharyngeal extension (HR adjusted for age, gender, chemotheraphy, and N category according to the seventh edition AJCC system). PSS: prestyloid space; RPS: retropharyngeal space; CS: carotid space; PVS: prevertebral space; MMS: medial pterygoid muscle of masticator space; LMS: lateral pterygoid muscle of masticator space and beyond; PS: parotid space.

3.5. Staging Categories for Parapharyngeal Extension. To assess the prognostic value and staging categories for different degrees of parapharyngeal extension in NPC, we divided T2–T4 patients (AJCC 2010 staging system) into four groups: group 1, mild parapharyngeal invasion; group 2, T3 without extensive parapharyngeal invasion; group 3, all T4 (excluding patients staged as T4 because of masticator space invasion); and group 4, extensive parapharyngeal extension. No significant difference was observed among these groups with respect to gender, age, N classification, or radiation technique (Table 3). The survival curves for OS, LRFS, and DMFS in these groups are shown in Figure 3. The OS, LRFS, and DMFS of patients with mild parapharyngeal extension were significantly higher than those of T3 patients without extensive parapharyngeal extension (P = 0.015, P = 0.008, and P < 0.001, resp.). By contrast, the OS, LRFS, and DMFS of patients with extensive parapharyngeal extension were close to those of patients with T4 disease (P = 0.052, P = 0.193, and P = 0.115, resp.). Hence, mild and extensive parapharyngeal extension should be classified as stage T2 and T4 disease, respectively.

4. Discussion

Parapharyngeal extension of NPC can occur via four pathways: lateral spread to the masticator space or prestyloid space; posterolateral spread to the carotid space or parotid space; posterior spread to the prevertebral space or retropharyngeal space; and inferior spread to the paraooropharyngeal space. In previous studies, investigators have focused on the prognostic significance of parapharyngeal extension in

...and extensive invasion (involvement of lateral pterygoid muscle and beyond of masticator space or parotid space).

Figure 2: HR for death according to anatomic site of parapharyngeal extension (HR adjusted for age, gender, chemotheraphy, and N category according to the seventh edition AJCC system).
Overall survival

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 108 120

Months after treatment

(a)

G1
G2
G3
G4

Factor
P
G2 0.015
G3 <0.001 <0.001
G4 <0.001 <0.001 0.052

(b)

G1
G2
G3
G4

Factor
P
G2 0.008
G3 <0.001 <0.001
G4 <0.001 <0.001 0.193

(c)

G1
G2
G3
G4

Figure 3: OS (a), LRFS (b), and DMFS (c) curves for patients with NPC stratified according to grade of parapharyngeal extension and T category. G1: mild parapharyngeal extension; G2: T3 without extensive parapharyngeal extension; G3: all T4 (excluding patients staged as T4 because of masticator space invasion); G4: extensive parapharyngeal extension.

To the best of our knowledge, no studies have focused on the subclassification of lateral, posterior, posterolateral, and inferior parapharyngeal spread in NPC. Our study was based on MRI findings and demonstrated that parapharyngeal extension should be subclassified into two risk grades: mild involvement (invasion of the medial pterygoid muscle of the masticator space or the carotid, prestyloid, prevertebral, or retropharyngeal space) and extensive involvement (invasion of the lateral pterygoid muscle of the masticator space and beyond or the parotid space). The OS, LRFS, and DMFS of patients with mild parapharyngeal extension were significantly higher than those of T3 patients, and patients with extensive parapharyngeal extension had OS, LRFS, and DMFS similar to those of patients with stage T4 disease; therefore, it seems reasonable that mild and extensive parapharyngeal extension should be classified as stages T2

NPC [1–12, 22–24]. However, the results of these studies are somewhat unclear for several reasons. First, the definition of parapharyngeal extension varies and always focuses on a single pathway of spread. For example, the findings reported by Chua et al. [1] and Sham and Choy [2] were based on lateral parapharyngeal spread; by contrast, Ma et al. [3] and Heng et al. [4] proposed that paraoropharyngeal extension should be included in the NPC staging system on the basis of inferior parapharyngeal spread. Second, the outcomes of most studies were based on diagnoses made by CT. With recent advances in the diagnosis of NPC due to the widespread availability of MRI, the management strategy and prognostic factors for this disease have been altered [25–27]. Given these uncertainties, it is important to reassess the prognostic value of parapharyngeal extension and to determine its appropriate subclassification.
and T4 diseases, respectively. This can offer considerable improvement over existing methods for subclassifications of parapharyngeal extension in patients with NPC and has the potential to provide clinicians with reliable information for prognostic prediction and personalizing therapy aimed at NPC patients.

In the fifth and sixth edition AJCC staging system for NPC, staging masticator space involvement was classified as stage T4 disease and defined as lateral tumor extension beyond the anterior surface of the lateral pterygoid muscle [13, 14]. The current, seventh edition includes an adjustment beyond the anterior surface of the lateral pterygoid muscle as stage T4 disease and defined as lateral tumor extension in NPC patients. This can offer considerable improvement over existing methods for subclassifications of parapharyngeal extension in NPC and has the potential to provide clinicians with reliable information for prognostic prediction and personalizing therapy aimed at NPC patients.

In the present study, all 1504 patients were treated with conventional techniques based on CT simulation, 3D-CRT, or IMRT, which ensure better tumor dose coverage. No significant difference in OS, LRFS, or DMFS was observed between patients with anterior carotid space invasion and patients with posterior carotid space invasion or between parapharyngeal extension and parapharyngeal space involvement. Therefore, we support the view that subclassification of carotid space involvement or parapharyngeal extension in NPC is unnecessary.

The retropharyngeal and prestyloid spaces are close to the nasopharynx and are the most common sites of parapharyngeal extension in NPC. The prevertebral space, located behind the retropharyngeal space, is also a high-risk site for tumor involvement. Prevertebral space involvement in hypopharyngeal or laryngeal carcinoma is regarded as unresectable disease (T4b) and is usually associated with poor survival [28]. However, excellent local control and long-term survival can be achieved in patients with prevertebral space involvement in NPC if they are treated with curative radiotherapy, especially IMRT. Our data indicate that the OS, LRFS, and DMFS of patients with prevertebral space involvement were approximately similar to those of patients with retropharyngeal or prestyloid space involvement. Therefore, involvement of the prevertebral space, together with the retropharyngeal and prestyloid spaces, may be classified as mild parapharyngeal extension. However, the prognostic importance of parotid space involvement in NPC has not been emphasized in previous studies. Our data indicated that parotid gland involvement was accompanied by lateral tumor spread to the lateral pterygoid muscle, and the prognostic importance of parotid gland involvement in NPC was similar to that of lateral pterygoid muscle invasion.

It should be stressed that pathologic confirmation of imaging findings is not possible in patients with NPC, who are typically treated with radiotherapy rather than surgery, thus determining the anatomic sites of parapharyngeal extension based on MRI alone could be inaccurate. Furthermore, the generality of our results could be reduced by the fact that some patients had incomplete follow-up data and that patients came from an area in southern China with a high incidence of NPC. Therefore, our proposals should be verified in subsequent studies.

### 5. Conclusions

Based on our data, we propose that parapharyngeal extension should be subclassified as mild or extensive and that mild and extensive parapharyngeal extension should be classified as stage T2 and stage T4 disease, respectively. Furthermore, these grades can facilitate staging of NPC and enable a more
tailored therapeutic approach with improved outcomes for this disease.

Disclosure

The authors alone are responsible for the content and writing of the paper.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Guo-Yi Zhang and Ying Huang contributed equally to this work.

Acknowledgments

This work was supported by Grants from the Natural Science Foundation of Guangdong Province (Grant S201040004296), the Science and Technology Planning Program of Guangdong Province (Grant 20120318050) and the Science and Technology Key Project of Foshan City (Grant 20100805).

References


